XmAb819
Phase 1Biologic
XmAb819 is one of 17 biologic programs targeting Clear Cell Renal Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Clear Cell Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Votrient
NovartisPhase 3
M6620
AstraZenecaPhase 2
Adavosertib
AstraZenecaPhase 2
Inlyta
PPrism Pharmaceuticals
Phase 2
Navmi
SSummit Therapeutics
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Zanzalintinib
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XmAb819. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- XXencor, Inc.